索利那新治疗慢性前列腺炎的效果分析

Effect analysis of solifenacin on patients with chronic prostatitis

目的:探究索利那新治疗慢性前列腺炎的效果。方法:选取60例慢性前列腺炎患者,将其随机分为对照组和索利那新组,每组各30例。对照组进行常规治疗,索利那新组在对照组基础上加用索利那新治疗。检测患者前列腺特异性抗原(PSA)、卵磷脂小体(SPL)水平及血清炎症因子、CD4+T细胞、CD8+T细胞水平;分析两组患者尿流率、NIH-CPSI评分和QOL评分。结果:治疗后,索利那新组平均尿流率、最大尿流率及QOL评分均高于对照组,差异有统计学意义(P<0.05);NIH-CPSI评分低于对照组(P<0.05);PSA、IL-1β、CRP、CD8+T细胞水平均低于对照组(P<0.05);SPL、CD4+T细胞水平均高于对照组(P<0.05)。结论:索利那新能减轻炎症反应,改善免疫功能,提高前列腺炎的临床治疗效果。

Objective:To investigate the effect of solifenacin on patients with chronic prostatitis.Methods:A total of 60 patients with chronic prostatitis were randomized into the control group and solifenacin group,each with 30 cases.The control group received conventional treatment,while the solifenaxin group were treated with solifenaxin on the basis of the treatment for the control group.Then,the levels of prostate spcific antigen(PSA)and small particle of lecitin(SPL),serum inflammatory factor,and CD4+T cell and CD8+T cell levels of patients were detected;and urinary flow rate,NIH-CPSI and QOL scores of patients were compared between both groups.Results:After treatment,compared with the control group,the average urinary flow rate,the maximum urinary flow rate,QOL score,and SPL and CD4+T cell levels of the solifenaxin group were higher,while NIH-CPSI score,PSA,IL-1β,CRP and CD8+T cell levels were lower,and the differences were statistically significant(P<0.05).Conclusion:The treatment of prostatitis patients with solifenaxin can reduce the inflammatory response,improve immune function,and improve the clinical therapeutic effect of patients with prostatitis.